Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives as Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase
- 26 January 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (3) , 1123-1139
Abstract
Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.Keywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (12ZR144280)
- Ministry of Education of the People's Republic of China
- Ministry of Science and Technology of the People's Republic of China (2012AA020308)
- Shanghai Municipal Education Commission (13SG32)
- Science and Technology Commission of Shanghai Municipality (13QH1401100, 14431902400)
- National Natural Science Foundation of China (21372078, 81102375, 81222046, 81230076, 81302697)
- Fok Ying Tung Foundation (141035)
This publication has 52 references indexed in Scilit:
- On Dihydroorotate Dehydrogenases and Their Inhibitors and UsesJournal of Medicinal Chemistry, 2013
- Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) InhibitorsMini-Reviews in Medicinal Chemistry, 2011
- Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cellsMolecular Cancer Therapeutics, 2009
- Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJournal of Neurology, 2009
- Pyrimidine pathways in health and diseaseTrends in Molecular Medicine, 2005
- Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane‐associated N‐terminal domainProtein Science, 2004
- E. coli Dihydroorotate Dehydrogenase Reveals Structural and Functional Distinctions between Different Classes of Dihydroorotate DehydrogenasesStructure, 2002
- Insight into the Chemistry of Flavin Reduction and Oxidation inEscherichia coliDihydroorotate Dehydrogenase Obtained by Rapid Reaction StudiesBiochemistry, 2001
- Leflunomide: mode of action in the treatment of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasiteBiochimica et Biophysica Acta (BBA) - General Subjects, 1995